Comparison of normal and tumorigenic endothelial cells: differences in thrombospondin production and responses to transforming growth factor-beta by RayChaudhury, Amlan et al.
Comparison of normal and tumorigenic
endothelial cells: differences in
thrombospondin production and responses
to transforming growth factor-beta
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation RayChaudhury, Amlan, William A. Frazier, Patricia A. D'Amore.
1994. Comparison of normal and tumorigenic endothelial cells:
differences in thrombospondin production and responses to
transforming growth factor-beta. Journal of Cell Science 107(Pt
1):39-46
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:36304245
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
INTRODUCTION
In contrast to the relatively quiescent endothelium of normal
adult blood vessels (Engerman et al., 1967; Hobson and
Denekamp, 1984), cultured endothelial cells (EC) have a high
labeling index (Folkman et al., 1979). The growth of cultured
EC is modulated by various agents, such as basic fibroblast
growth factor (bFGF), which stimulates their proliferation
(Vlodavsky et al., 1979; Baird et al., 1985a,b) and transform-
ing growth factor type-beta (TGF-b ), a potent growth inhibitor
(Baird and Durkin, 1986; Frater-Schroder et al., 1986; Heimark
et al., 1986). Under appropriate circumstances certain factors
such as bFGF (Montesano et al., 1986) and phorbol esters
(Montesano and Orci, 1985) induce EC in vitro to form tube-
like structures similar to microvessel networks, whereas TGF-
b inhibits the phorbol ester-induced in vitro ‘angiogenesis’
(Muller et al., 1987). Thus, cultured EC constitute a system in
which regulation of EC growth, migration and differentiation
parallels the in vivo events of angiogenesis and in which the
roles of different growth effectors may be studied. 
An approach that may further elucidate mechanisms
involved in the regulation of EC behavior is a comparison of
normal EC to cell lines that are derived from normal EC but
that have altered growth properties. One such EC line,
bEND.3, was generated by infecting cultured mouse brain
capillary EC with a retrovirus carrying the polyoma middle
T oncogene (Montesano et al., 1990). bEND.3 cells, unlike
cultured normal EC, have an indefinite life span, an acceler-
ated doubling time and are not significantly contact-inhibited.
In addition, they have increased cell-associated proteolytic
activity that appears to account for their irregular morpho-
genetic behavior in vitro, including formation of cyst-like
cavities rather than tube-like structures in fibrin gels
(Montesano et al., 1990). The endothelial character of
bEND.3 cells, however, is demonstrated by the fact that they
synthesize von Willebrand factor and have receptors for
acetylated low density lipoprotein. When injected into
embryonic and newborn mice, bEND.3 cells induce rapidly
growing tumors that are lethal in embryonic mice but spon-
taneously regress in newborn and young mice (W. Risau,
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Cultured endothelial cells constitutively synthesize signifi-
cant levels of thrombospondin, an extracellular matrix-
associated protein with reported anti-angiogenic proper-
ties. However, two murine endothelial cell lines, bEND.3
and Py-4-1, which have been immortalized with polyoma T
oncogenes and which generate vascular malformations in
vivo, produce little or no thrombospondin though bEND.3
(but not Py-4-1) growth is inhibited by the addition of
exogenous thrombospondin. In addition, Py-4-1 cells are
not growth-inhibited by transforming growth factor-beta,
a potent endothelial inhibitor. These results indicate that
these two cell lines may be useful tools in understanding the
role and mechanism of action of thrombospondin and
transforming growth factor-beta in endothelial cell biology.
A role for thrombospondin in vascular development is
further suggested by the observation of significant differ-
ences in the levels of thrombospondin mRNA and protein
between capillary and aortic endothelial cells. Transform-
ing growth factor-beta-1 treatment of normal endothelial
cells increases steady-state levels of thrombospondin
mRNA and protein and results in extensive deposition of
thrombospondin into the extracellular matrix. In contrast,
transforming growth factor-beta-1 has little effect on
thrombospondin levels in the tumorigenic endothelial cell
lines. In view of our earlier finding that contact between
endothelial cells and mural cells generates activated trans-
forming growth factor-beta-1, and the fact that throm-
bospondin is present in a fibrillar network around vascular
structures in vitro, we speculate that modulation of throm-
bospondin production and distribution by transforming
growth factor-beta may be a physiological process to enjoin
stabilization of vessels and cessation of vessel growth.
Key words: angiogenesis, endothelial cell, extracellular matrix, TGF-
b , thrombospondin, vascular malformation
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personal communication). These tumors resemble vascular
malformations, consisting of a central blood-filled cavern sur-
rounded by few layers of smooth muscle cells. These obser-
vations suggest that in bEND.3 cells one or more of the
processes governing normal endothelial growth, migration
and differentiation have been altered or eliminated in this EC
line.
Another EC line, Py-4-1, was isolated from vascular tumors
arising in transgenic mice carrying the entire polyoma early
genetic region (Dubois et al., 1991). Py-4-1 cells express all
three polyoma T-antigens and, like bEND.3 cells, grow at a
faster rate than normal capillary EC. When injected into mice,
Py-4-1 cells also give rise to tumors that resemble vascular
malformations. The tumors form stable structures that can exist
for several months, although they are invariably lethal. Thus,
Py-4-1 cells and bEND.3 cells may share certain common
features that differ from normal EC and that may contribute to
their tumorigenic phenotype. 
To gain insight into mechanisms that regulate EC growth
and differentiation, we have begun to characterize differences
between these tumorigenic cells and normal EC. We have
focused our attention on two molecules, TGF- b 1 and throm-
bospondin-1 (TSP-1), which are known to regulate EC
behavior. Previous work from our laboratory (Antonelli-
Orlidge et al., 1989) and others (Sato and Rifkin, 1989) has
established that when EC and mural cells (smooth muscle
cells and pericytes) are grown in coculture, physical contact
between the two cell types results in the activation of TGF-
b which inhibits EC growth. This observation may be signif-
icant in view of the extensive contacts that EC and mural
cells make throughout the vasculature (Rhodin, 1968). The
possibility that TGF- b is activated locally within the vascu-
lature, together with the reported effects of TGF- b on angio-
genesis (Muller et al., 1987; Merwin et al., 1990), strongly
suggests that it plays a role in vascular development and
maintenance. 
TSP-1, a matrix-associated trimeric glycoprotein, has gained
interest as an EC-modulating agent; a fragment called gp-140,
whose expression in some cells is regulated by a tumor sup-
pressor gene, has been found to be anti-angiogenic in vivo
(Good et al., 1990). In addition, expression of TSP-1 gene in
cultured fibroblasts (Penttinen et al., 1988) and smooth muscle
cells (Majack et al., 1990; Kobayashi and Yamamoto, 1991) is
regulated by TGF-b 1, raising the possibility of the coordinate
involvement of TGF-b and TSP in the regulation of angiogen-
esis. Soluble TSP-1 has also been reported to be an inhibitor
of EC growth (Bagavandoss and Wilks, 1990; Taraboletti et
al., 1990). 
In this paper we describe the results of our studies
comparing normal EC and bEND.3 cells with regards to the
action of TGF-b 1 and their production of TSP-1. Our results
indicate a selective loss or reduction of TSP-1 mRNA and
protein in the tumorigenic cells and a TGF-b -induced increase
in and redistribution of TSP-1 in normal but not tumorigenic
cells. However, tumorigenic and normal cells are equally
inhibited by the addition of exogenous TSP. These findings,
together with observations of differences in TSP-1 expression
between large and microvessel EC, support the concept that
TSP may contribute to the development and stabilization of
vascular structures.
MATERIALS AND METHODS
Cell culture
Bovine capillary EC, supplied by C. Butterfield and Dr J. Folkman
(The Children’s Hospital, Boston, MA), were grown on gelatinized
surfaces (1.5% in PBS) in Dulbecco’s modified Eagle’s medium
(DMEM; JRH Biosciences, Lenexa, KS) containing 10% calf serum
(CS) and supplemented with 2 mM glutamine, 100 units/ml each of
penicillin and streptomycin (Irvine Scientific, Santa Ana, CA) and 2-
3 ng/ml human recombinant bFGF (provided by Takeda Chemical
Industries, Ltd, Osaka, Japan). Rat brain EC, provided by Dr Susan
Doctrow (Alkermes Inc, Cambridge, MA), were grown on gelatinized
surfaces in 10% FCS-containing DMEM/F12 (1:1) supplemented
with glutamine, penicillin and streptomycin as above, and 100 m g/ml
heparin and 12.5-25 m g/ml endothelial cell growth supplement
(Sigma, St. Louis, MO). Rat aortic EC, provided by Dr John Doukas
(University of Massachusetts School of Medicine, Worcester, MA),
were grown on fibronectin- (2 m g/cm2) and gelatin (1.5% in PBS)-
coated surfaces in the same medium as the rat brain EC. EC from
bovine aortae were isolated by gently scraping the intimal surface
with a scalpel blade and were grown in 10% CS-containing DMEM.
bEND.3 cells were supplied by Dr Werner Risau (Max Planck Institüt,
Martinsried, Germany) and were grown in DMEM containing 10%
CS. Py-4-1 cells were provided by Dr Vicki Bautch (University of
North Carolina, Chapel Hill, NC) and were grown in DMEM con-
taining 10% CS. All cells were grown in 10% CO2 at 37°C. Human
recombinant TGF-b 1 was provided by Oncogen (Seattle, WA). At
confluence cells were passaged with trypsin-EDTA (0.05%
trypsin/0.53 mM Na4EDTA) for 1-5 minutes. To grow cells in TGF-
b , media were aspirated, cells were washed with PBS and refed with
fresh media containing serum and TGF-b 1 (at the indicated concen-
trations) but no other growth factors. 
Northern analysis 
Total cellular RNA was isolated by lysis of cells with guanidinium
isothiocyanate followed by ultracentrifugation on CsCl (Chirgwin et
al., 1979). Total cellular RNA (15 m g) from each sample was resolved
on formaldehyde-agarose gels and transferred to nitrocellulose paper
(Thomas, 1980). Blots were hybridized to 32P-labeled cDNA probes
(1-5· 106 dpm/ml) in a hybridization solution consisting of 50%
deionized formamide, 750 mM NaCl, 75 mM sodium citrate, 20 mM
HEPES, pH 7.4, 1 mM EDTA, 10 m g/ml tRNA, 0.01% BSA, 0.02%
Ficoll-400, 0.02% polyvinylpyrrolidone-360, 10 m g/ml sonicated
salmon sperm DNA (Sigma) at 42°C. After hybridization, blots were
washed with 0.1% SDS, 0.1 · SSC at 50°C and exposed to an X-ray
film overnight (or longer if necessary).
Probes
All probes used for northern blots were labeled with 32P. TSP-1 probe
was made against a 4.4 kb BamH1-HindIII fragment digested from
the full-length human cDNA (Hennessy et al., 1989). A probe for
secreted protein acidic and rich in cysteine (SPARC) was made
against a 550 bp BamHI-EcoRI mouse cDNA fragment, supplied by
Dr Helene Sage (University of Washington, Seattle, WA). Glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) probe was made
against a 1.3 kb PstI fragment digested from rat GAPDH cDNA (Fort
et al., 1985).
Immunofluorescence
Cells were grown on Lab-Tek chamber slides for 3 days, fixed in 4%
paraformaldehyde in PBS for 15 minutes at room temperature, per-
meabilized with 0.2% Triton X-100 and stained with 15 m g/ml of anti-
human TSP-1 monoclonal antibody (Prater et al., 1991) for 30-60
minutes at 37°C. Cells were then washed three times with PBS (10
minutes each) and incubated with a 1:75 dilution of rhodamine-
labeled goat anti-mouse IgG (Boehringer Mannheim, Indianapolis,
A. RayChaudhury and others
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IN) as above. Slides were mounted with antifade mounting medium
(90% glycerol, 0.1% phenylenediamine, pH 9 in PBS), coverslipped
and viewed with a Zeiss microscope.
Cell proliferation assays
Cells were plated at a density of 5000 cells/cm2 in 24- or 48-well
dishes in DMEM containing serum. The next day unattached cells
were removed and the number of cells plated (To) was determined in
one well. The cells were then refed with the same medium and the
factor being studied (3-4 wells per data point). Rat brain EC were
plated at higher densities because they did not plate or grow well at
low densities in the absence of growth factors. Assays were conducted
over a 3-day period and cells were counted electronically using a
Coulter counter. Statistical analyses were performed using the
InStat® program (Graph Pad, San Diego, CA).
RESULTS
TGF-b 1 inhibits proliferation of rat brain, bovine
capillary and bEND.3 EC but not of Py-4-1 cells
Because of the potentially important role of TGF-b in EC
growth control, we compared the response of normal and
tumorigenic EC to TGF-b 1. Our earlier studies had shown that
0.25-0.5 ng/ml TGF-b 1 effected maximal inhibition of bovine
capillary and aortic EC growth (D’Amore and Smith, 1993).
We used a concentration of 1 ng/ml (two- to four-fold higher
than the maximum inhibitory concentration) for all our studies.
TGF-b 1 at 1 ng/ml significantly inhibited the growth of rat
brain EC, bovine capillary EC, and bEND.3 cells, but not Py-
4-1 cells (Fig. 1). Further studies revealed that the prolifera-
tion of Py-4-1 cells was not inhibited by concentrations of
TGF-b 1 up to 10 ng/ml or by 10 ng/ml TGF- b 2 (data not
shown). We have not extensively studied TGF-b 2 because its
inhibitory effect on EC is much weaker than that of TGF-b 1
(Jennings et al., 1988). Py-4-1 cells are one of the few
examples of EC that retain endothelial characteristics, but are
not inhibited by TGF-b . 
Steady-state level of TSP mRNA is very low in two
tumorigenic EC lines 
Both TGF-b 1 and TSP-1 have been implicated in the control
of angiogenesis, and TGF-b 1 has been shown to drastically
affect the production of TSP in several cell types (Penttinen et
al., 1988; Majack et al., 1990). Thus, we compared production
of TSP-1 in the tumorigenic EC lines to production by normal
EC and assessed the effect of TGF-b 1 on TSP-1 production.
Total RNA was isolated from rat brain capillary EC, bEND.3
cells, and Py-4-1 cells grown at their log phase for 3 hours in
the absence and presence of TGF-b 1 (1 ng/ml). Northern
analysis of RNA from these cells with a TSP-1 cDNA probe
revealed that normal EC produce substantial amounts of the 6
kb TSP-1 transcript (Fig. 2, lane 1). TSP-1 mRNA was unde-
tectable in bEND.3 cells and Py-4-1 cells showed very low
levels (Fig. 2, lanes 3 and 5, respectively). TGF-b 1 increased
the steady-state level of TSP-1 mRNA in the normal cells
about two-fold (Fig. 2, lane 2), whereas TGF-b 1 treatment of
bEND.3 cells (which prior to TGF-b had no steady-state TSP-
1 mRNA) showed a low level of TSP-1 mRNA (Fig. 2, lane
4) and TGF-b 1-treated Py-4-1 cells showed a slight increase
in steady-state levels of TSP-1 mRNA (Fig. 2, lane 6).
A number of functions ascribed to TSP are shared by
SPARC, a glycoprotein secreted by cultured EC and vascular
smooth muscle cells (Sage and Bornstein, 1991). SPARC has
no structural homology to TSP-1, but like TSP-1, is an ‘anti-
adhesive’ molecule and is reported to inhibit EC growth (Funk
and Sage, 1991). These similarities between SPARC and TSP
led us to investigate whether the expression of SPARC is also
altered in bEND.3 and Py-4-1 cells. Northern analysis of RNA
Fig. 1. Effect of TGF-b on the growth of normal and
tumorigenic EC. EC were grown in 2 cm2 wells of 24-
well dishes and assayed for the effect of TGF-b (1
ng/ml) on growth over 3 days. T0 = cell number at start
of assay; bars represent + s.d.. For rat cells, bovine
aortic cells and bEND.3 cells P£ 0.0001; for Py-4-1
cells P=0.4013.
TGF b 1 (1 ng/ml)
TGF b 1 (1 ng/ml) TGFb 1 (1 ng/ml)
TGFb 1 (1 ng/ml)
T0 
T0 
T0 
T0 
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isolated from bEND.3 cells, Py-4-1 cells and rat brain EC with
a SPARC cDNA probe showed no significant difference in
steady-state levels of the 2.3 kb SPARC mRNA between
normal EC and the EC lines (Fig. 2). In addition, TGF-b 1 did
not significantly affect SPARC mRNA levels in any of the cells. 
TGF-b 1 increases and redistributes TSP-1 protein in
normal EC 
To determine whether the TGF-b 1-induced increase in steady-
state TSP-1 mRNA was associated with changes in synthesis
of TSP protein, indirect immunofluorescence was performed
on rat brain EC, bEND.3 cells and Py-4-1 cells grown for 3
days with and without TGF-b 1. As shown in Fig. 3a, more than
half of the untreated rat brain EC stained positively for TSP-
1, with some cells staining very intensely. The variability in
the staining among the cells is probably due to differences in
cell cycle, since production of TSP-1 has been shown to be cell
cycle-dependent in smooth muscle cells and these cells are not
growing synchronously (Majack et al., 1990). TSP-1 labeling
in TGF- b 1-treated rat brain EC was observed in almost every
cell and the level of staining was more intense in the TGF- b 1-
treated cells than in untreated cells (Fig. 3b). Moreover, more
TSP-1 was localized in the extracellular matrix of TGF-b 1-
treated cells than the untreated cells. In contrast, in the absence
of TGF-b virtually none of the bEND.3 (Fig. 3c) or Py-4-1
(Fig. 3e) cells stained positively for TSP-1. TGF-b -treated
bEND.3 cells, showed a low level TSP labeling in a small
number of cells (Fig. 3d); TSP protein was undetectable in
TGF-b -treated Py-4-1 cells (Fig. 3f). Thus, whereas normal EC
have substantial TSP mRNA and protein, which is increased
by treatment with TGF-b , tumorigenic EC have little to no TSP
and their TSP levels are not significantly influenced by TGF-b .
Levels of TSP-1 mRNA and protein differ between
large and small vessel EC 
The fact that the tumorigenic EC lines have no TSP-1 and form
cavernous vascular malformations in vivo led us to postulate
that TSP-1 may be involved in the determination of vessel
diameter. We, therefore, compared TSP-1 levels in EC cultured
from large vessels and from microvessels. Cultured rat aortic
EC grown in the presence and absence of TGF-b 1 were stained
for TSP-1 protein. Untreated rat aortic EC had very low levels
of cell-associated TSP (Fig. 4a) compared to rat brain capillary
EC (Fig. 4c). However, after exposure to TGF- b 1 for 3 days,
there was a striking change in TSP-1 production and distribu-
tion; all cells treated with TGF-b 1 stained strongly for TSP-1,
and there was abundant TSP-1 in the extracellular matrix
(Fig.4b). 
To rule out the possibility that the difference in TSP levels
between the aortic and capillary TSP-1 was species-specific,
steady-state levels of TSP-1 mRNA and TSP-1 protein were
examined in cultured bovine capillary EC and aortic EC.
Capillary EC had significantly higher levels of TSP-1 mRNA
than aortic EC (Fig. 5a). In addition, nearly all of the capillary
EC stained strongly for TSP-1 (Fig. 5b), whereas aortic EC
stained much more weakly, with some cells barely labeled
(Fig. 5c). As was true for rat EC, TGF-b 1 treatment of both
bovine capillary and aortic EC led to a substantial increase in
steady-state TSP-1 mRNA, and higher cell- and extracellular
matrix-associated TSP-1 protein (data not shown). These
experiments were carried out with cells at different densities
and passage numbers, yielding essentially the same results.
Thus, comparison of TSP-1 levels in capillary and aortic cells
from two species suggests that capillary EC reproducibly syn-
thesize more TSP-1 than aortic cells. 
Normal and tumorigenic EC are both inhibited by
exogenous TSP
In light of the reported ability of TSP to inhibit both the pro-
liferation and migration of EC and the absence of TSP pro-
duction by tumorigenic EC, we were interested in comparing
the effects of TSP on the growth of normal capillary EC and
bEND cells. Addition of TSP to rapidly growing cells led to a
dose-dependent decrease in their proliferation (Fig. 6).
Maximal growth inhibition of about 50% for both the normal
and tumorigenic EC was observed at 10 ug/ml TSP. 
DISCUSSION
Motivated by the demonstrated roles for TSP-1 and TGF-b 1 in
the regulation of EC growth and function, we compared TSP-
1 production and responses to TGF- b 1 in normal EC and two
murine EC lines and found significant differences. Compared
to normal EC, these two EC lines produce little or no TSP.
Upon TGF- b treatment, normal EC revealed increased levels
of TSP mRNA and protein. The bEND.3 cells, which prior to
TGF- b treatment have no TSP mRNA or protein, respond to
TGF- b by expressing a low level of TSP mRNA with scattered
cells staining for TSP protein. Py-4-1 cells have a low level of
TSP mRNA, which is increased following exposure to TGF-
b , but immunostaining reveals no detectable TSP protein, sug-
gesting that a post-transcriptional mechanism is responsible for
the lack of protein. The specificity of the absence of TSP-1 is
highlighted by the observation that the steady-state levels of
SPARC, a protein that shares many features with TSP, do not
differ between the normal and tumorigenic EC. Our observa-
A. RayChaudhury and others
Fig. 2. Northern analysis of steady state levels of TSP and SPARC
mRNA in normal and tumorigenic EC grown in the presence and
absence of TGF-b 1. Total cellular RNAs are from: lanes 1 and 2, rat
brain EC; 3 and 4, bEND.3 cells; 5 and 6, Py-4-1 cells. Lanes 1, 3
and 5 are from untreated cells and lanes 2, 4 and 6 from cells treated
with TGF-b 1 (1 ng/ml) for 3 hours. mRNA sizes: TSP-1, 6 kb;
SPARC, 2.3 kb; GAPDH, 1.5 kb.
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tion of significant levels of SPARC mRNA in bEND.3 cells is
consistent with a recent report that these cells synthesize and
secrete functional SPARC protein (Sage, 1992). A significant
difference between these two cell lines is that the bEND.3
cells, but not Py-4-1 cells, are inhibited by TGF-b 1, suggest-
ing that resistance to the growth-inhibitory effect of TGF-b 1
may not play a role in the development of vascular malforma-
tions. Other differences have been reported between these
immortalized cells and normal EC; Montesano et al. (1990)
demonstrated that bEND.3 and other polyoma middle T-
expressing endothelioma cells have increased cell-associated
proteolytic activity, which accounts for some of their abnormal
morphogenetic characteristics in vitro. 
Though our observations do not demonstrate a causal link
between the absence of TSP and the tumorgenicity of these EC
lines, the known properties of TSP do support a role for TSP
Fig. 3. Immunocytochemical localization of TSP in normal EC and tumorigenic EC. Rat brain capillary EC (a,b), bEND.3 cells (c,d) and Py-4-
1 cells (e,f) were grown on Lab-Tek 4-chamber slides as described in Materials and Methods, immunostained with an anti-TSP monoclonal
antibody and visualized at · 32 magnification. Untreated cells (a,c,e); TGF-b -treated cells (1 ng/ml for 3 days) (b,d,f). 
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in the control of EC function. A number of reports have
indicated TSP to be a regulator of vessel formation. Good et
al. (1990) identified gp-140, an inhibitor of angiogenesis and
capillary EC migration regulated by a tumor-suppressor gene,
to be a fragment of TSP. More recently, this inhibitory activity
has been localized to a 19 amino acid region of the central 70
kDa stalk of the molecule (Tolsma et al., 1993). In addition,
this fragment inhibits both bFGF-stimulated migration and
DNA synthesis by cultured EC. Iruela-Arispe et al. (1991a)
found an inverse correlation between TSP protein mRNA pro-
duction and the extent of cord formation in cord-containing EC
cultures. In contrast, SPARC mRNA levels, which are not
affected in the established EC lines we studied, are actually
upregulated in cord-containing EC cultures (Iruela-Arispe et
A. RayChaudhury and others
Fig. 4. Effect of TGF-b on TSP production by rat aortic EC. Rat
aortic EC were grown on Lab-Tek chamber slides, stained for TSP
with anti-TSP monoclonal antibody and visualized at · 32
magnification. Untreated cells (a); TGF-b -treated cells (1 ng/ml for 3
days) (b); untreated rat capillary cells (c) (· 50).
Fig. 5. Production of TSP by bovine capillary and aortic EC. TSP
levels in rapidly growing bovine capillary and aortic EC were
determined by northern hybridization and immunofluorescence.
(a) Northern analysis of TSP mRNA: lane 1, bovine capillary EC;
lane 2, bovine aortic EC. GAPDH mRNA levels used as internal
control. Localization of TSP protein in bovine capillary EC (b) and
bovine aortic EC (c).
a
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al., 1991b). Thus, the absence of TSP in tumorigenic EC may
contribute to the lack of normal growth control mechanisms
evidenced by the formation of vascular malformations in vivo.
A recent report has described the knockout of the TGF-b 1
gene in mice by homologous recombination (Shull et al.,
1992). Although these mice suffer from multifocal inflamma-
tory disease, they exhibited no developmental abnormalities.
Total disruption of several other genes thought to be develop-
mentally important, including c-src, tenascin, and myoD, have
not yielded any major developmental failures either, and expla-
nations ranging from gene redundancy to nonfunctional protein
production during embryogenesis have been offered (for a per-
spective see Erickson, 1993). As long as the molecular basis
of development is not understood in greater detail, it suffices
to say that the knockout of one member of a multigene family
encoding proteins with similar functions, such as the TGF-b s,
may not yield a convincing clue to the role of that gene in
development and morphogenesis.
The treatment of normal EC with TGF-b 1 leads to an
increase in cell- and extracellular matrix-associated TSP-1.
This is consistent with the concept that the action of TGF-b
may be mediated, at least in part, via alterations in the extra-
cellular matrix. In support of our hypothesis, Iruela-Arispe
(1991a) reported that in cord-containing EC cultures, TSP dis-
tributes in a fibrillar array around the EC cords and suggested
a role for TSP in stabilizing the vessels. Our previous obser-
vation that physical contact between EC and mural cells leads
to the activation of TGF-b has led us to postulate that the
locally activated TGF-b plays an important role in the regula-
tion of vascular growth.
The TGF-b -stimulated deposition of TSP-1 in the microen-
vironment of the vessel may represent a physiological
mechanism that contributes to the cessation of vessel growth.
Thus, the absence of TSP in tumorigenic EC may contribute
to the lack of normal growth control mechanisms evidenced by
the formation of vascular malformations in vivo. 
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